Monitoring Skin Immune System (SIS) alterations in HS during treatment with biologics.

Monitoring Skin Immune System (SIS) alterations in HS during treatment with biologics. - SIS alterations in HS during biologic therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49777

Enrollment

Registered

2020-11-03

Start date

2020-07-15

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acne inversa Verneuil's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Age *18 years. 2. Indication for and starting with a biologic. 3. Able and willing to give written informed consent and to comply with the study requirements.

Exclusion criteria

Exclusion criteria: 1. Use of any medication potentially affecting the skin immune system or skin microbiome.

Design outcomes

Primary

Measure	Time frame
The main study parameter is the change in gene expression profile in lesional, peri-lesional an uninvolved skin in patients with HS after 12 weeks of biologic treatment.	—

Secondary

Measure	Time frame
- Microbial changes profile in lesional, peri-lesional an uninvolved skin in patients with HS after 12 weeks of biologic treatment. - Immunohistochemical changes profile in lesional, peri-lesional an uninvolved skin in patients with HS after 12 weeks of biologic treatment. - Change in protein expression profile in lesional, peri-lesional an uninvolved skin in patients with HS after 12 weeks of biologic treatment.	—

Measure

Time frame

- Microbial changes profile in lesional, peri-lesional an uninvolved skin in patients with HS after 12 weeks of biologic treatment. - Immunohistochemical changes profile in lesional, peri-lesional an uninvolved skin in patients with HS after 12 weeks of biologic treatment. - Change in protein expression profile in lesional, peri-lesional an uninvolved skin in patients with HS after 12 weeks of biologic treatment.

—

Countries

Netherlands

Outcome results